BTWM
REGN icon

Baker Tilly Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Baker Tilly Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$879K Buy
1,410
+46
+3% +$31.3K 0.19% 104
2026
Q1 		$1.05M Buy
1,364
+57
+4% +$43.6K 0.26% 76
2025
Q4 		$1.01M Buy
1,307
+23
+2% +$15.6K 0.25% 81
2025
Q3 		$722K Buy
1,284
+4
+0.3% +$2.26K 0.16% 118
2025
Q2 		$672K Buy
1,280
+125
+11% +$69.8K 0.24% 95
2025
Q1 		$733K Buy
1,155
+641
+125% +$441K 0.29% 90
2024
Q4 		$366K Sell
514
-222
-30% -$186K 0.14% 160
2024
Q3 		$774K Buy
736
+137
+23% +$152K 0.34% 72
2024
Q2 		$630K Sell
599
-432
-42% -$419K 0.26% 94
2024
Q1 		$992K Buy
1,031
+3
+0.3% +$2.85K 0.18% 125
2023
Q4 		$903K Sell
1,028
-243
-19% -$200K 0.15% 147
2023
Q3 		$1.05M Sell
1,271
-2,338
-65% -$1.84M 0.17% 124
2023
Q2 		$2.59M Buy
3,609
+77
+2% +$59.4K 0.27% 82
2023
Q1 		$2.9M Buy
3,532
+183
+5% +$138K 0.33% 67
2022
Q4 		$2.42M Sell
3,349
-84
-2% -$62K 0.3% 77
2022
Q3 		$2.37M Buy
3,433
+222
+7% +$140K 0.32% 71
2022
Q2 		$1.9M Sell
3,211
-437
-12% -$284K 0.25% 86
2022
Q1 		$2.55M Buy
3,648
+537
+17% +$340K 0.28% 75
2021
Q4 		$1.97M Buy
3,111
+435
+16% +$267K 0.21% 95
2021
Q3 		$1.62M Buy
2,676
+552
+26% +$343K 0.21% 93
2021
Q2 		$1.19M Buy
2,124
+200
+10% +$101K 0.19% 117
2021
Q1 		$910K Sell
1,924
-208
-10% -$101K 0.19% 131
2020
Q4 		$1.03M Buy
+2,132
New +$1.15M 0.32% 77

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Baker Tilly Wealth Management's REGN Position: Q2 2026 in Review

Baker Tilly Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 3.4% in Q2 2026, buying an estimated $31.3K and bringing the position to 1,410 shares worth $879K. The position accounts for 0.19% of the portfolio, ranked #104.

Baker Tilly Wealth Management first reported a position in REGN in Q4 2020 and has held it in 23 quarters since. The position peaked at $2.9M in Q1 2023. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Baker Tilly Wealth Management held 1,410 shares of Regeneron Pharmaceuticals worth $879K as of Q2 2026.
  • Baker Tilly Wealth Management bought 46 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $31.3K.
  • Regeneron Pharmaceuticals made up 0.19% of Baker Tilly Wealth Management's portfolio in Q2 2026, its #104 holding.
  • Baker Tilly Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Baker Tilly Wealth Management's Regeneron Pharmaceuticals position peaked at $2.9M in Q1 2023.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Baker Tilly Wealth Management's 13F filing for Q2 2026, filed 17 Jul 2026.